Navigation Links
Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference

PHILADELPHIA, Jan. 15, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference.

Mr. Doman will make a corporate presentation to prospective corporate partners and investors at 9:00 AM EST on Wednesday, January 22nd.  The Company's presentation will be delivered in Sandpiper Bay, Florida.

At the time of the presentation, a live audio and high-definition video webcast of Mr. Doman's presentation and a copy of the presentation materials will be available in the Events section of the Company's website at, or through the Noble Financial websites: or  Echo recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access.  You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate.  The webcast and presentation will also be archived on for 90 days following the event. 

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including the statement about the corporate presentation, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104                                       

Connect With Us:
- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  Yesterday Congresswoman ... Vaccines Holly Springs manufacturing site located in ... the facility has produced Flucelvax ® (Influenza Vaccine) using ... potential for faster start-up and is not reliant on ... Limited acquired the influenza vaccines business of Novartis AG ...
(Date:10/12/2015)... 13, 2015 the United States ... a non-clinical capacity. --> the United States ... a non-clinical capacity. --> The University of Texas MD ... the first high field (1.5 Tesla) MRI-guided linear accelerator in ... system will be operating in a non-clinical capacity. Royal ...
(Date:10/12/2015)... , Oct. 12, 2015  Former White House Spokesman, and ... for the House Narcotics Committee, Robert Weiner , and ... Policy." The two emphasize that this is now a potential ... to Jeb Bush , Carly Fiorina to ... the newest federal statistics, which they call "a shocker: 23 ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... workflow solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and ... AXUG Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an age where ... were 36 percent lower per square foot than in 2009. The Williamsport Regional Medical ... heating and cooling has decreased by eight percent. , According to Facilities Management ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a leading embedded ... See3CAM_CU40, the industry’s first RGB-IR pixel format camera with a USB 3.0 interface ... e-con’s See3CAM family of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 ...
(Date:10/13/2015)... Los Angeles, CA (PRWEB) , ... October 13, ... ... has published an in-depth review of Anik Singal's newly launched "Publish Academy" ... scaling a digital publishing business opened for enrollment today, and marketers around the ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... Omega-3, a first-of-its kind product that targets the unique health needs of ... of the American Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, ...
Breaking Medicine News(10 mins):